Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - Haizheng Shengcai (688203) expects a significant decline in net profit for the fiscal year 2025, projecting a profit of 7.5 million to 9.5 million yuan, representing a year-on-year decrease of 73.24% to 78.88% [2] Financial Performance - The company faces downward pressure on product sales prices, which has compressed the gross profit margin [2] - A decrease in interest income and foreign exchange gains has led to an increase in financial expenses for the period [2] - The transition of some construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further squeezing profits [2]

Core Viewpoint - The company, Haizheng Shengcai (688203.SH), expects a significant decline in net profit for the year 2025, projecting a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company is projected to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million to 7.5 million yuan, reflecting a year-on-year decrease of 75.98% to 82.39% [1] Operational Insights - The company has seen steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - Despite the growth in sales revenue due to deepening and expanding the domestic market, the company faces downward pressure on product sales prices due to market competition [1] Financial Challenges - There has been a year-on-year decrease in interest income and foreign exchange gains, leading to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

本期业绩变化的主要原因：报告期内，公司生产经营工作稳步推进，主营产品产销量呈现增长趋势，公 司不断深耕和拓宽国内市场，销售额实现增长。但是受市场竞争影响，公司产品销售价格面临下行压 力，致使产品毛利空间承压。本期利息收入和汇兑收益同比减少，导致本期财务费用增加。募投项目在 建工程部分转固，导致折旧、税金等费用增加，进而压缩了本期利润。 格隆汇1月30日丨海正生材(688203.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润为750万元到950万元，与上年同期相比，将减少2600.46万元到2800.46万元，同比减少 73.24%到78.88%。归属于母公司所有者的扣除非经常性损益的净利润为550万元到750万元，与上年同 期相比，将减少2372.89万元到2572.89万元，同比减少75.98%到82.39%。 ...

格隆汇1月30日｜海正生材公告，预计2025年年度实现归属于母公司所有者的净利润为750万元到950万 元，与上年同期相比，将减少2600.46万元到2800.46万元，同比减少73.24%到78.88%。归属于母公司所 有者的扣除非经常性损益的净利润为550万元到750万元，与上年同期相比，将减少2372.89万元到 2572.89万元，同比减少75.98%到82.39%。 ...

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 7.5 million to 9.5 million yuan, which represents a year-on-year decrease of 73.24% to 78.88% [1] Group 1 - The company cites market competition as a key factor leading to downward pressure on product sales prices, which in turn compresses gross profit margins [1] - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the current period [1] - Ongoing construction projects related to fundraising have been capitalized, resulting in increased depreciation and tax expenses, further impacting current profits [1]

证券代码：688203 证券简称：海正生材 公告编号：2026-02 浙江海正生物材料股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润为 750 万元到 950 万元，与上年同期相比，将减少 2,600.46 万元到 2,800.46 万元，同比减少 73.24%到 78.88%。 （2）归属于母公司所有者的扣除非经常性损益的净利润为 550 万元到 750 万元，与上年同期相比，将减少 2,372.89 万元到 2,572.89 万元，同比减少 75.98% 到 82.39%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 四、风险提示 截至本公告披露日，公司未发现影响本次业绩预告内容准确性的重大不确定 因素。 五、其他说明事项 本公告所载预计财务数 ...

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. is experiencing a decline in both revenue and net profit, alongside notable changes in shareholder structure and financing activities [1][2]. Group 2 - On January 26, Haizheng Biomaterials' stock fell by 1.45%, with a trading volume of 38.68 million yuan. The financing buy-in amount was 4.03 million yuan, while the financing repayment was 4.27 million yuan, resulting in a net financing buy of -0.24 million yuan [1]. - As of January 26, the total margin trading balance for Haizheng Biomaterials was 54.57 million yuan, accounting for 3.24% of its market capitalization, which is above the 70th percentile of the past year [1]. - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1]. - As of September 30, the number of shareholders decreased by 10.22% to 6,695, while the average circulating shares per person increased by 17.43% to 18,538 shares [2]. - For the period from January to September 2025, Haizheng Biomaterials reported a revenue of 621 million yuan, a year-on-year decrease of 5.74%, and a net profit attributable to shareholders of 4.91 million yuan, down 85.34% year-on-year [2]. - The company has distributed a total of 42.49 million yuan in dividends since its A-share listing [2]. - Notable changes in institutional holdings include new entries from several funds, with the top ten circulating shareholders now including new investors such as招商均衡优选混合A and招商品质发现混合A [2].

Core Viewpoint - The company, Haizheng Biomaterials, specializes in resin-based polylactic acid (PLA) and has obtained various international certifications, indicating its commitment to product safety and compliance in global markets [1]. Group 1: Product and Certifications - The main product of the company is resin-based polylactic acid [1]. - The company has achieved FDA food contact safety certification in the United States, compliance certification in Japan, and has completed REACH registration in the European Union [1]. Group 2: Market and Sales - The company's products are exported overseas, including to EU countries [1]. - Sales in Europe are primarily conducted through direct sales to major clients and distribution via dealers, with revenue from this region accounting for a relatively low proportion of the company's total operating income [1].

Core Viewpoint - The company focuses on the research, production, and sales of polylactic acid (PLA) materials, highlighting the superior performance of its high-purity PLA resin in various applications [2]. Group 1: Company Focus - The company specializes in the development of polylactic acid materials [2]. - The high-purity PLA resin produced by the company is noted for its excellent performance [2]. - Applications of the company's PLA resin include fiber spinning, 3D printing, and injection molding [2]. Group 2: Market Applications - Currently, the company has not ventured into the medical applications of polylactic acid materials [2].